Back to search

Article

Effects of enzalutamide, apalutamide, and darolutamide in metastatic hormone-sensitive prostate cancer with or without docetaxel: a systematic review and network meta-analysis

2022-08-31

Abstract excerpt

<h4>Background: </h4> Recently, treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has been significantly advanced. Androgen deprivation therapy (ADT) was the standard of care for decades. However, as the primary mHSPC treatment, several next-generation androgen receptor inhibitors (NGARIs), such as enzalutamide, apalutamide, and darolutamide are increasingly used. <h4>Methods: </h4>: A systematic r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bb19f920-d796-5a9d-a6a3-8237c152de93
DOI
10.21203/rs.3.rs-1851705/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effects of enzalutamide, apalutamide, and darolutamide in metastatic hormone-sensitive prostate cancer with or without docetaxel: a systematic review and network meta-analysisDOI 10.21203/rs.3.rs-1851705/v1
Risks associated with the combination of Darolutamide and Docetaxel in interstitial lung disease : a pharmacovigilance study based on the FAERS databaseSemantic proximity
Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysisSemantic proximity
Apalutamide Monotherapy in Metastatic Hormone-Sensitive Prostate Cancer: a Viable Alternative to First Generation Anti-Androgen Agents to Avoid the Flare Phenomenon and an Effective Treatment to Achieve Early PSA ResponseSemantic proximity
Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study.Semantic proximity
Current State of Adjuvant Hormone Therapy in Prostate Cancer and in the Management of Pelvic Nodal Recurrence: A Narrative ReviewSemantic proximity
Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate CancerSemantic proximity
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).Semantic proximity
Olaparib for Chinese Metastatic Castration-resistant Prostate Cancer: A Real-World Study of Efficacy and Gene Predictive AnalysisSemantic proximity
Inhibition of Galectin-1 and androgen receptor axis enhances enzalutamide treatment in enzalutamide resistant prostate cancerSemantic proximity
Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancerSemantic proximity
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: data from a translational study.Semantic proximity
Synergistic combination therapy with ONC201 or ONC206, Enzalutamide and Darolutamide in preclinical studies of castration-resistant prostate cancerSemantic proximity
Select a neighboring publication to make it the new centre.